(Q38807857)

6 September 2017

Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness (English)

1 reference

6 September 2017

Vishal Ahuja

1

1 reference

PubMed ID

27076180

6 September 2017

Chia-Hung Chou

series ordinal

2

1 reference

6 September 2017

1 June 2016

1 reference

6 September 2017

Current diabetes report

1 reference

6 September 2017

16

1 reference

6 September 2017

6

1 reference

6 September 2017

47

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-016-0744-4

6 September 2017

0 references

cites work

Diabetes: Advances in Diagnosis and Treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

National trends in treatment of type 2 diabetes mellitus, 1994-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Use of antidiabetic drugs in the U.S., 2003-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Use of exenatide and liraglutide in Denmark: a drug utilization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Trends in antidiabetic prescription patterns in Japan from 2005 to 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Projecting the future diabetes population size and related costs for the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Responding to an FDA warning--geographic variation in the use of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

An overview of metformin in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0744-4

FDA warning and removal of rosiglitazone from VA national formulary.

21 January 2018

1 reference

12 December 2020

Metformin as first choice in oral diabetes treatment: the UKPDS experience.

1 reference

12 December 2020

Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert

1 reference

12 December 2020

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis

1 reference

12 December 2020

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events

1 reference

12 December 2020

10.1007/S11892-016-0744-4

Identifiers

DOI

1 reference

PubMed ID

27076180

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

27076180